SciTech is a clinical stage, biopharmaceutical company that has developed a proprietary nano-delivery system (SciTech Delivery Vehicle - SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide, our lead API, has been shown in numerous clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity. The patented combination of the new SDV and fenretinide has led to SciTech’s first drug product, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives.
Intellectual Property: SciTech is the inventor, co-owner and exclusive licensee of U.S. Patent No. 8,709,379 (issued April 29, 2014) titled “Liposomal Nanoparticles and Other Formulations of Fenretinide for Use in Therapy and Drug Delivery”. International patent coverage includes the major global oncology markets: Canada, EU, Australia and New Zealand. SciTech has recently filed a provisional patent titled “Use of Fenretinide Nanoparticles for Immunotherapeutic Cancer Treatment” (U.S. Patent Application No. 62/769,822 November 20, 2018) claiming the immune oncology effects of ST-001 nanoFenretinide.
The Mission of SciTech Development is to rapidly advance the development of meaningful therapeutic agents previously hampered by formulation and delivery hurdles which can now be overcome with SciTech’s proprietary technology. SciTech believes these enhanced agents can have immense value in treating diseases with high unmet clinical need in attractive markets. In the case of fenretinide (ST-001 nanoFenretinide), by creating the first ever triglyceride-free intravenous vehicle, the company has successfully completed the task of finally delivering on the promise of fenretinide as an anticancer agent.
Earle T. Holsapple III,
President & Co-Founder
Earle has successfully served as CEO/COO of six profitable midsize companies. He developed and raised the initial funding for the SoftVueTM technology for Karmanos Cancer Institute, It is a novel breast cancer detection product now in clinical trials with Delphinus Medical Technologies, Inc.
Mike has close to 40 years of pharmaceutical industry experience that includes R&D, product development, sales & marketing, licensing & acquisitions. He is the President and Chief Operating Officer of Ferndale Pharma Group which comprises companies that specialize in the development, manufacture, marketing, sale and distribution of a wide variety of healthcare products including prescription and over-the counter drug products and medical devices.
Ralph is an accomplished pharmacologist and principal inventor of the SciTech drug delivery technology. He presently directs a multi-laboratory program at the NCI-Frederick, NIH, where he manages the effort to create innovative approaches for evaluating and developing new drug compounds. He has worked part-time supporting SciTech’s development, patenting and commercialization activities.
Michael Burns, PhD,
Ralph E. Parchment, PhD,
Inventor & Co-Founder
Ayad Al-Katib, MD,
Dr. Al-Katib recently retired as the Director of the Van Elslander Cancer Center at St. John Providence Health where he remains head of the hematology department. He also is a professor at the Wayne State University School of Medicine. He has extensive clinical and management experience in overseeing clinical activities. He is a lymphoma specialist with extensive experience in running clinical trials including some of those for the well-known Michigan startup, ProNAi.
20+ years technology commercialization; Principal Advisor (PA) to the Los Angeles Regional Technology Alliance’s (Larta) Life Sciences Technology Group, a PA in the National Institutes of Health and National Science Foundation Commercialization Assistance Programs (NIH CAP & NSF CAP); Founder of MVS Solutions and Kollodis BioSciences.
Attorney, Immix Law Group,
General Counsel, Former CEO of
a startup pharmaceutical tool company. She specializes in business and SEC law.
SciTech also has a strong and experienced Board of Advisors comprised of pharmaceutical and biotech company executives, senior product development managers, and highly skilled clinicians and scientists.
Louis M. Scarmoutzos, PhD
Elizabeth H. Kraus,
Andrew J. Stumpf
Mr. Stumpf brings 20+ years of experience as a finance professional in private equity, investment banking, corporate finance, and public accounting. Mr. Stumpf serves on the board of directors of a public diversified holding company as a member on the audit, compensation and nominating committees. Mr. Stumpf is a partner with Storm Lake Capital, a private equity firm that invests in middle market companies. Mr. Stumpf also performs in a finance capacity for several portfolio companies with responsibilities including financial and strategic planning and budgeting, financial reporting and year-end audit and tax filings.
Christine D. Copple, PhD
Senior Vice-President, Strategy
Dr. Copple brings over three decades of experience as a corporate officer and board member in multiple biotechnology enterprises ranging from oncology to neural stem cells to pharmaceutical manufacturing equipment and BioMed IT. As a technology company founder and executive, her responsibilities have included fund raising, business development, operations, build out, cGMP manufacturing build/design, regulatory affairs, human resources, international marketing and sales, corporate communication, PR, investor relations, legislative liaison and R&D.
Dr. Moiin is board certified in Dermatology and is a practicing Dermatologist. He maintains affiliations with major medical centers in the Detroit metro area, including Detroit Medical Center, St. John's Hospital, St. Mary's Hospital and William Beaumont Hospital. Dr. Moiin received his bachelor's degree in pharmacology and master's degree in biology from the University of California, Santa Barbara. He received further training in pharmacy at the University of California, San Francisco and awarded his Doctor of Medicine degree from the University of California, Davis.
Ali Moiin, MD
Division Manager, Topical Products
John Doux, MD,
MBA, Palo Alto Investors
Gregory Kalemkerian, MD,
Professor of Medicine, University of Michigan
Timothy Kuzel, MD,
Hematologist/Oncologist, Rush University Medical Center
Brian Leyland-Jones, MD, PhD,
Avera Cancer Institute, Chief Medical Officer & Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR)
Kenneth Massey, PhD,
Senior Director, Venture Development, WSU
Steve Munk, PhD,
Formerly CEO, Ash Stevens, Inc
Michael W. Young,
Principal, biomedwoRx: Life Sciences Consulting, Biotech Executive,
Cutaneous Lymphoma Foundation Board Director.